CCCC catalysts
Catalysts and events linked to CCCC, newest first.
CCCC stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS 2026-09-26 · Up | clinical biomarker validation driving targeted oncology pipeline valuation | C4 Therapeutics presented Phase 1 biomarker data demonstrating robust T-cell activation at IMS. | Not recorded |
| C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data 2026-09-26 · Up | biotech pipeline derisking via validated Phase 1 biomarker mechanisms | Presented positive biomarker and T-cell activation data at 23rd IMS Annual Meeting. | Not recorded |
| C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data 2026-09-26 · Up | clinical pipeline de-risking via IMS biomarker validation | Source details IMS Annual Meeting biomarker presentation showing T-cell activation in cemsidomide trials. | Not recorded |
Do these developments change your position?
Review CCCC alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-26C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker DataCCCC PFE-1.01%
- 2026-09-26C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker DataCCCC-1.01%
- 2026-09-26C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMSCCCC PFE-1.01%
- 2026-09-26C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker DataCCCC PFE-1.01%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.